Sinclair Pharma Regulatory News (SPH)

Sinclair IS Pharma plc

Share Awards

London, 17 July 2014 Sinclair IS Pharma plc (SPH.L), ("Sinclair" or the "Group") the international specialty pharma company, announces that the following Directors and the Group's Chief Financial Officer have been allocated the following units under the terms of an updated Value Creation Plan ("VCP"):

A further 1,575 VCP Units have been allocated to other senior employees of the Group with 1,945 units remaining unallocated.

The VCP was approved by shareholders at a general meeting in January 2011 VCP units have no value at grant but have the potential to convert into awards of nil-cost options. The VCP units entitle participants to share in 15% of the return created for shareholders above a hurdle, measured at five annual measurements dates over the VCP plan period. The first measurement date will follow publication of the Group's results for the year ended 30 June 2015, expected to be in September 2015. VCP units will only convert to awards of nil-cost options if the annual hurdle of 16% is achieved with a base price of 37p representing the initial starting point, 23.3% above the closing price on 16 July 2014. No payment has been made for the grant of these awards.

50% of any nil-cost options granted will become exercisable on the fifth measurement date with the remaining 50% of the options exercisable on the first anniversary of the fifth measurement date.

All VCP awards granted in 2011 have been surrendered. Additional details of the VCP scheme are set out in the Group's report and accounts to 30 June 2013 available on the Group's website.

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Clare Terlouw

Notes to Editors:

About Sinclair IS Pharma plc - www.sinclairispharma.com 

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.